A QSAR study of some Phenoxyacetamide derivatives as a MAO-A inhibitor

Abstract

http://dx.doi.org/10.21276/IJRDPL.22780238.2018.7(1).2931-2940 ABSTRACT: Antidepressants are the most prescribed therapy for depression. The prevailing theory is that antidepressants increase the concentration of one or more brain chemicals (neurotransmitters) that nerves in the brain use to communicate with one another. The neurotransmitters affected by antidepressants are norepinephrine, serotonin, and dopamine. In order to address the need for new MAO inhibitors with less side effects, we can aim compounds previously discovered for their potential as MAOIs. Among them, safinamide was reported to be a potent anti-MAO B agent, and milacemide, which was found to be a potent MAO inhibitor and a prodrug for glycine. The present work deals with the aim because Currentely available MAO inhibitors {Isocarboxazid (Marplan), Phenelzine (Nardil), Selegiline (Emsam), Tranylcypromine (Parnate) etc} develop side effects because they do not selectively for MAO-A and MAO-B. So, the present study is focused to develop potent selective MAO-A inhibitors, to treat depression, that may be of better pharmacological activity with less adverse effect.